抗乙型肝炎病毒核苷(酸)类似物使用情况分析  

Utilization of anti-hepatitis B virus drugs nucleos( t) ide analogues

作　　者：曹辉[1] 殷萍萍[1] 王坚[1] 燕丹[1] 

机构地区：[1]南京市第二医院药学部,南京210003

出　　处：《医学研究生学报》2013年第9期963-965,共3页Journal of Medical Postgraduates

摘　　要：目的抗病毒治疗是治疗慢性乙型肝炎的关键。文中通过分析南京市第二医院抗乙型肝炎病毒(Hepatitis B virus,HBV)核苷(酸)类似物使用情况,评价该类药物的用药情况及变化趋势。方法对2009年1月至2011年12月核苷(酸)类似物的销售金额、用药频度(defined daily dose,DDDs)、日均费用(defined daily dose cost,DDDc)等进行统计分析。结果 2009-2011年核苷(酸)类似物的销售金额分别为2876.56、3542.85和4628.87万元,逐年明显递增。各种药物的DDDs基本呈逐年上升趋势,特别是恩替卡韦,2009-2011年分别为127 869、222 243、432 565,使用频率越来越高。结论核苷(酸)类似物已经成为慢性HBV治疗的重要方法,临床治疗中应根据患者的具体情况合理选择药物,以提高药物治疗的安全性、有效性和经济性。Objective Antiviral therapy is the key to the treatment of chronic hepatitis B （HB）. This article is to investigate and analyze the use of the anti-HB virus drugs nucleos （t）ide analogues in Nanjing Second Hospital. Methods We conducted statis- tic analyses on the gross consumption, defined daily dose （DDD） and defined daily dose cost （DDDc） of nucleos （t）ide analogues be- tween January 2009 and December 2011. Results The sums of sales of nucleos （t） ide analogues were increased year by year, 2876.56, 3542.85 and 4628.87 million yuan respectively in 2009, 2010 and 2011. So were the DDDs, 127 869, 222 243 and 432 565 respectively, in the three years. Conclusion Nucleos （t）ide analogues have become an important choice in the treatment of chronic HBV infection. However, rational selection of anti-HBV drugs according to each patient＇s specific condition is necessitated for improving the safety, efficacy and economy of medication.

关 键 词：核苷（酸）类似物 慢性乙型肝炎 用药频度 日均费用 

分 类 号：R978.7[医药卫生—药品]